An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Sign Up to like & getrecommendations! Published in 2019 at "CNS Drugs"
DOI: 10.1007/s40263-019-00656-w
Abstract: Treatment with nusinersen has demonstrated significant and clinically meaningful benefits in clinical trials in infants and children with spinal muscular atrophy (SMA). The objective of this analysis was to characterize the safety of nusinersen across… read more here.
Keywords: infants children; onset sma; safety; children symptomatic ... See more keywords